TY - JOUR
T1 - Late Toxicity After 3-Dimensional External Beam Radiotherapy Among Children With Cancer
T2 - A Systematic Review
AU - Beijer, Josien G. M.
AU - Teepen, Jop C.
AU - Streefkerk, Nina
AU - Heijnen, Richard M.
AU - Janssens, Geert O.
AU - Kremer, Leontien C. M.
AU - van Dalen, Elvira C.
AU - Ronckers, C. cile M.
N1 - Funding Information: C.M.R. reported a personal grant from the Dutch Cancer Society (grant no: UVA2012-5517). J.G.M.B. reported a grant from the Dutch Cancer Society (grant no: UVA2015-7655). Publisher Copyright: © 2022 Lippincott Williams and Wilkins. All rights reserved.
PY - 2022/5/1
Y1 - 2022/5/1
N2 - Radiotherapy has evolved from 2-dimensional conventional radiotherapy (2D-RT) to 3-dimensional planned radiotherapy (3D-RT). Because 3D-RT improves conformity, an altered late health outcomes risk profile is anticipated. Here, we systematically reviewed the current literature on late toxicity after 3D-RT in children treated for cancer. PubMed was searched for studies describing late toxicity after 3D-RT for childhood cancer (below 21 y). Late toxicity was defined as somatic health outcomes occurring ≥90 days after treatment. We identified 13 eligible studies, describing most frequently head/neck area tumors. Included studies reported on crude frequencies of late toxicities including subsequent tumors and conditions of organ systems. Three studies offered a global assessment of the full spectrum of late toxicity; one study compared toxicities after 2D-RT and 3D-RT. Incidence rates were typically not provided. Heterogeneity in study characteristics, small study sizes and short follow-up times precluded multivariable modeling and pooling of data. In conclusion, among the first pediatric cohorts treated with 3D-RT, a broad variety of late toxicity is reported; precise estimates of incidence, and contributions of risk factors are unclear. Continued systematic evaluation of well-defined health outcomes in survivors treated with 3D-RT, including proton therapy, is needed to optimize evidence-based care for children with cancer and survivors.
AB - Radiotherapy has evolved from 2-dimensional conventional radiotherapy (2D-RT) to 3-dimensional planned radiotherapy (3D-RT). Because 3D-RT improves conformity, an altered late health outcomes risk profile is anticipated. Here, we systematically reviewed the current literature on late toxicity after 3D-RT in children treated for cancer. PubMed was searched for studies describing late toxicity after 3D-RT for childhood cancer (below 21 y). Late toxicity was defined as somatic health outcomes occurring ≥90 days after treatment. We identified 13 eligible studies, describing most frequently head/neck area tumors. Included studies reported on crude frequencies of late toxicities including subsequent tumors and conditions of organ systems. Three studies offered a global assessment of the full spectrum of late toxicity; one study compared toxicities after 2D-RT and 3D-RT. Incidence rates were typically not provided. Heterogeneity in study characteristics, small study sizes and short follow-up times precluded multivariable modeling and pooling of data. In conclusion, among the first pediatric cohorts treated with 3D-RT, a broad variety of late toxicity is reported; precise estimates of incidence, and contributions of risk factors are unclear. Continued systematic evaluation of well-defined health outcomes in survivors treated with 3D-RT, including proton therapy, is needed to optimize evidence-based care for children with cancer and survivors.
KW - 2-dimensional conventional radiotherapy
KW - 3-dimensional radiotherapy
KW - childhood cancer
KW - late toxicity
KW - systematic review
UR - http://www.scopus.com/inward/record.url?scp=85128795726&partnerID=8YFLogxK
U2 - https://doi.org/10.1097/MPH.0000000000002445
DO - https://doi.org/10.1097/MPH.0000000000002445
M3 - Review article
C2 - 35398857
SN - 1077-4114
VL - 44
SP - 117
EP - 134
JO - Journal of pediatric hematology/oncology
JF - Journal of pediatric hematology/oncology
IS - 4
ER -